Fedratinib Re-emerges as FDA-Approved Treatment of Myelofibrosis

Oct 17, 2019

Andrew Kuykendall, MD, discusses the background to the JAK2 inhibitor fedratinib (Inrebic), which was approved by the FDA in August 2019 for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post–polycythemia vera or post–essential thrombocythemia MF.

Andrew Kuykendall, MD, assistant member at the Moffitt Cancer Center, discusses the background to the JAK2 inhibitor fedratinib (Inrebic), which wasapproved by the FDA in August 2019 for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis(MF), including post—polycythemia vera or post–essential thrombocythemia MF.

Kuykendall says fedratinib has an interesting story. It’s a relatively old drug that had previously been through extensive clinical trials years ago and has now re-emerged. He calls this a rising-from-the-ashes story to describe the evolution of fedratinib and its move toward the treatment landscape for patients with MF.

Related Content